Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

AMSTERDAM, The Netherlands, October 21, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. The decision was made contrary to the positive recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, and the Committee for Advanced Therapies (CAT), which provides guidance on advanced therapeutics such as gene and cell therapy. These expert groups after extensive review and analysis of the data advised the CHMP that Glybera should be approved now under exceptional circumstances. The CHMP Rapporteurs, SAG and the CAT concluded that data from three Glybera clinical trials demonstrated meaningful evidence of clinical efficacy, without any major safety concerns. However, the CHMP is not bound to follow this advice. While AMT carefully reviews the grounds of the CHMP refusal, the Company will focus on strategic advancement of other promising projects in its development pipeline.

"The decision from the CHMP is disappointing particularly because a treatment will now not be available to European patients who suffer from LPLD for whom Glybera is the only therapeutic option. We are encouraged by the validation provided by the CHMP Rapporteurs, Scientific Advisory Group and the Committee for Advanced Therapies regarding our gene therapy platform, indicating that safety is not an issue," said Jörn Aldag, CEO of AMT. "We are evaluating thoroughly and expediently the next steps available to the Company and will provide an update on the future developments of our validated gene therapy pipeline."

On Tuesday October 25, 2011 at 10:00 AM CET, AMT will provide an update on
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report Strategic ... report provides in-depth analysis of the current trends ... capital segments of the financial industry, bearing in ... impact on the future of emerging biotechnology companies ... identifies regions of the world that are attracting ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... Tough, ultralight foam of atom-thick sheets can be made ... invented at Rice University. , In microscopic images, ... with floors and walls that reinforce each other. The ... and walls of graphene oxide that self-assemble with the ... researchers say the foam could find use in structural ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2
... , ... , ,• LC-MS/MS • DeCyder MS • differential analysis, ... Ettan™ MDLC was used in conjunction with tandem mass spectrometry (MS/MS) ... the olive tree, Olea europaea . DeCyder™ MS Differential Analysis ...
... K. Hölscher, M. Richter-Roth, and B. Felden ... , ... chromatography can often be improved by optimizing the imidazole concentration in ... and yield of the protein of interest. We determined a concentration ...
... , DNA Genotek Inc., Ottawa, ON, Canada , ... Oragene works well with TaqMan SNP Genotyping Assays. , SNPs ... detected., , ... abundant, and are estimated , to occur at 1 out ...
Cached Biology Technology:Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 2Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 3Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 5Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 6Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 7Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 8Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 9Addition of imidazole during binding improves purity of histidine-tagged proteins 2Oragene is compatible with TaqMan SNP genotyping 2Oragene is compatible with TaqMan SNP genotyping 3
(Date:7/29/2014)... Schools of Dentistry (UM SOD) and Medicine (UM ... a five-year $10.7 million grant award from the ... of the National Institutes of Health to study ... (STDs). The grant, which renews a previous $12 ... direction for the research by studying chlamydial and ...
(Date:7/29/2014)... news for parents of preterm babies latest research from ... time they become teenagers, the brains of many preterm children ... , A study conducted by the University,s Robinson Research ... child experiences no brain injury in early life, their cognitive ... their term-born peers. , However, the results of the study, ...
(Date:7/29/2014)... the first to show that while the impact of ... negative effects may be reduced by maintaining a healthy ... participants who exercised, slept well and ate well had ... healthy lifestyles, even when they had similar levels of ... in the department of psychiatry at UCSF. "It,s very ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Preterm children's brains can catch up years later 2Healthy lifestyle may buffer against stress-related cell aging, study says 2
... and Biological Sciences Research Council (BBSRC) have opened up ... our ability to produce disease- and pest-resistant crops in ... July) in the journal Science . An ... the University of Warwick, has used a systems biology ...
... Continued reliance on a strategy of setting aside ... to stem global biodiversity loss, according to a comprehensive ... Progress Series . Despite impressively rapid growth of ... over 100,000 in number and covering 17 million square ...
... on an old solar cell design sends light ricocheting ... by 26 percent. By engineering alternating layers ... from the University of Minnesota has improved the efficiency ... as 26 percent. These cells, known as dye-sensitized solar ...
Cached Biology News:Plant immunity discovery boosts chances of disease-resistant crops 2Ongoing global biodiversity loss unstoppable with protected areas alone: Study 2Ongoing global biodiversity loss unstoppable with protected areas alone: Study 3Ongoing global biodiversity loss unstoppable with protected areas alone: Study 4
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
...
Polaroid black & white positive, 3 x 4 inch pack film, ISO 3000/ 36 ASA DIN (20 expsures). For use in the Polaroid Direct Copy Camera (PHC34)....
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
Biology Products: